India's Leading Strategy Conference for Industry Executives
Life Science Biotech | Pharma | Bio Services | Digital Healthcare | Medtech
The pharma industry innovated, pivoted, conducted trials at breakneck speeds and came up with solutions and vaccines to combat the global Covid challenge in 2020. By the end of 2021, large portion of the populations would be vaccinated and moving beyond Covid, and Life would have a permanent digital component in every facet of activity. It is time to discuss the change drivers of the new next, the emerging post-Covid era for the entire biopharma and healthcare spectrum.
The speed at which COVID-19 vaccines have been developed and rolled out is a huge achievement for the pharma and biotech industries across the globe, particularly the scientific community. Given its decisive contributions to global response to the ongoing pandemic, this may represent an opportunity to reset the conversation for the life sciences industry and enhance its investment into R&D. In addition, the mergers & acquisitions side of the life sciences companies is going from strength to strength and we will probably see more activity there in the coming year.